Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development

Area of Science:

• Pharmacology
• Biomathematics
• Pediatric Medicine

Background:

• Pediatric drug dosing traditionally relies on linear scaling from adult data, which can lead to inaccurate and potentially harmful doses due to children's unique physiology.
• Ontogeny significantly impacts drug absorption, distribution, metabolism, and excretion (ADME) in children, necessitating specialized dosing strategies.

Purpose of the Study:

• To review the principles and necessity of physiologically based pharmacokinetic (PBPK) models in pediatric drug development.
• To elucidate the application of PBPK models in understanding pediatric drug ADME.
• To explore the prospects and regulatory acceptance of PBPK modeling in pediatric pharmacology.

Main Methods:

• Discussion of the fundamental principles underlying PBPK modeling.
• Review of existing literature on pediatric PBPK model development and application.
• Analysis of how PBPK models account for developmental changes in pediatric physiology.

Main Results:

• PBPK models provide a mechanistic understanding of drug behavior in pediatric populations.
• A successful example of PBPK-guided pediatric drug dose selection has been approved by regulatory agencies.
• PBPK modeling facilitates optimized and safer drug dosing for children.

Conclusions:

• Physiologically based pharmacokinetic (PBPK) modeling is essential for advancing pediatric drug development.
• PBPK models enable precise dose selection, mitigating risks associated with traditional scaling methods.
• The application of PBPK models holds significant promise for improving pediatric pharmacotherapy and regulatory science.